CION Ameerpet
An immature teratoma is a malignant germ cell tumour of the ovary, and it is a different disease from the ovarian cancer that almost everything written online describes. It mostly affects teenagers and women in their twenties, is usually still confined to one ovary when it is found, and is graded 1 to 3 — and that grade, more than the stage, decides what treatment follows. In almost every case the uterus and the opposite ovary stay where they are.
A teratoma is a tumour built from tissue belonging to all three layers of the early embryo. That is why these tumours can contain hair, skin, cartilage, fat, teeth and glandular tissue, which sounds alarming the first time anyone reads it and is in fact the ordinary biology of a germ cell tumour. Most teratomas of the ovary are mature: the tissue inside them is fully formed, the tumour is benign, and it is what doctors call a dermoid cyst.
An immature teratoma is the malignant member of that family. It also contains tissue from all three germ layers, but some of that tissue has not finished developing — almost always primitive neuroectoderm, the tissue that would otherwise have gone on to form brain and nerve. That immature component is the whole reason it is classed as a cancer, and the amount of it is what gives the tumour a grade. It is the second commonest malignant ovarian germ cell tumour after dysgerminoma, and searches for malignant teratoma ovary usually land on this diagnosis.
Then the part that matters most on the day you are told. This is a cancer and it is treated as one. It is also a cancer that behaves very differently from the ovarian cancer described in the general ovarian cancer guide, which is a disease of women over 50 that begins in the surface lining of the ovary and tube. An immature teratoma is usually still confined to one ovary when it is found, it responds well to chemotherapy when chemotherapy is needed, and the uterus and the opposite ovary are left in place in almost every case. BRCA, family history and reproductive history have no established link with it at all.
The same family of tumour, separated by one word on the pathology report. A dermoid is removed and that is the end of it. An immature teratoma needs staging, and sometimes chemotherapy.
Graded 1, 2 or 3 by how much immature tissue the pathologist finds. In most ovarian cancers the stage governs treatment. Here the grade usually does.
Standard surgery removes the affected ovary and its tube and leaves the uterus and the other ovary alone, including in most women whose disease has spread.
An immature teratoma is graded by how much immature tissue — almost always primitive neuroectoderm, the tissue that would have gone on to form brain and nerve — the pathologist can find on the most involved slide. The system dates to Norris and colleagues in 1976 and divides these tumours into grades 1, 2 and 3. The current WHO classification recommends collapsing that into two tiers, low grade (grade 1) and high grade (grades 2 and 3), because that is the division that actually changes what treatment is given. It makes immature teratoma one of the few ovarian cancers where the grade, rather than the stage, is the number the plan turns on — and it is the reason nothing can be decided until the removed tumour has been examined properly. Source: Norris HJ, Zirkin HJ, Benson WL, Cancer (1976); WHO Classification of Tumours — Female Genital Tumours (5th ed.); NCCN Guidelines for Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer.
The word teratoma covers benign tumours, malignant ones, and a couple of things in between. Most of the confusion that reaches our clinic comes from not knowing which one the report is describing.
| Tumour | Typical age | Is it cancer? | What it usually means |
|---|---|---|---|
| Immature teratoma | Teens and twenties | Yes — a malignant germ cell tumour | Graded 1 to 3. Surgery for everyone; whether chemotherapy follows depends mainly on the grade and on whether it was completely removed. |
| Mature cystic teratoma (dermoid) | Any age, commonest in the reproductive years | No — benign | Removed surgically, usually with the ovary itself preserved. No staging, no chemotherapy, no oncology follow-up. |
| Monodermal teratoma, such as struma ovarii | Reproductive years onwards | Usually benign | Made up predominantly of one tissue type, most often thyroid. Occasionally behaves malignantly, which is uncommon enough to need a specialist opinion. |
| Mature teratoma with malignant transformation | Usually over 40 | Yes — but a different cancer | A cancer arising inside a long-standing dermoid, most often a squamous carcinoma. Managed as that cancer, not as a germ cell tumour. |
| Mixed germ cell tumour containing immature teratoma | Teens and twenties | Yes | Treated according to its most aggressive component. A markedly raised AFP usually points to a yolk sac element sitting alongside the teratoma. |
| Dysgerminoma | Teens and twenties | Yes | The commonest malignant ovarian germ cell tumour, and a different one. Different markers, different thresholds for chemotherapy. |
*The confusion we see most often is between an immature teratoma and an ordinary dermoid cyst. The two can look similar on a scan, they are entirely different diagnoses, and only the pathologist, examining the removed tissue, can separate them. Where each sits in the wider family is set out in our guide to germ cell ovarian tumours in young women.
Almost every consequential decision in immature teratoma is written somewhere on the pathology report or the pre-operative bloods. These are the parts worth understanding before you are asked to agree to anything.
The grade reflects how much immature neuroectodermal tissue can be seen on the slide that contains the most of it. A tumour with only a trace is grade 1; one where immature tissue is found readily across the field is grade 3, with grade 2 in between. The rest of the tumour may look entirely ordinary — cartilage, skin, glands — and it is only that immature fraction that is being measured.
The current WHO classification asks pathologists to report this as low grade, meaning grade 1, or high grade, meaning grades 2 and 3, because that is the split treatment actually turns on. If your report gives a number rather than a tier, translate it that way. A grade 1 tumour that was removed intact and properly staged is often followed with surveillance alone; a high-grade tumour usually leads to a conversation about chemotherapy.
FIGO staging is the same system used across ovarian cancer: stage I is confined to the ovary or ovaries, stage II has spread within the pelvis, stage III involves the abdominal cavity or its lymph nodes, and stage IV means spread further afield. Most immature teratomas are stage I when found, because they tend to grow quickly and announce themselves as a mass rather than creeping quietly across the abdomen.
The stage still matters — it decides how much surgery and how much treatment. But in this tumour it does not carry the weight it carries in the epithelial ovarian cancers, where a stage III diagnosis substantially changes the outlook. Immature teratoma is chemosensitive, and advanced disease in a young woman is usually still treated with curative intent and with the uterus and opposite ovary preserved.
Sometimes the surgeon finds small nodules scattered over the peritoneum, the lining of the abdominal cavity, and the report describes them as gliomatosis peritonei. The word looks frightening on paper. What it actually describes is deposits made up of fully mature glial tissue — mature brain-type tissue, with none of the immature component that makes the ovarian tumour a cancer.
Peritoneal deposits are graded separately from the ovarian tumour, and mature deposits are graded as zero. That distinction is important, because deposits of this kind do not carry the poor outlook that immature implants would. They are usually followed rather than treated aggressively. If your report mentions this, ask specifically whether the implants were mature or immature: the answer changes the plan, and the two are easy to conflate when reading the summary line alone.
Three germ cell markers are checked before surgery, along with a pregnancy test. AFP is mildly raised in some pure immature teratomas, so a small elevation is not in itself alarming. A markedly raised AFP is different: it suggests the tumour also contains a yolk sac component, and a mixed germ cell tumour is treated according to its most aggressive part rather than its teratoma part.
Beta-hCG is also raised in pregnancy, which is why the pregnancy test comes first — not an assumption about you, but a step that stops a result being misread. LDH is non-specific here and is more useful in dysgerminoma. The reason all of them are taken before the operation is simply that a pre-operative baseline is what makes the post-operative fall interpretable; taken afterwards for the first time, they answer far less.
A small number of ovarian teratomas, mature and immature alike, trigger an immune reaction against the brain known as anti-NMDA receptor encephalitis. It can begin with anxiety, agitation, hallucinations, memory difficulty or a change in personality, and go on to seizures, abnormal movements and a reduced level of consciousness. Young women with it are sometimes admitted under psychiatry before anyone scans the pelvis.
It is uncommon, and nothing on this page should make you expect it. It is worth naming for one reason: if a young woman has an ovarian mass and unexplained neurological or psychiatric symptoms, the two need to be considered together rather than by separate teams. Removing the tumour is a central part of treating the encephalitis, and outcomes are considerably better when the connection is made early.
What a family needs on day one is rarely another scan. It is forty-five minutes with someone who can say plainly what the grade means, whether chemotherapy follows the surgery, and what happens to fertility.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Bring the scan and the pathology report — the grade is written on it, and most of the questions that actually matter follow from there.
The sequence is short and reasonably predictable. Surgery comes first for everyone, the grade arrives afterwards, and that grade decides whether anything else is needed.
Standard surgery removes the involved ovary and its fallopian tube and leaves the uterus and the opposite ovary in place. That is not a concession made for the sake of fertility at the cost of the outcome; it is standard management for this tumour, and it holds for most young women even where disease has spread beyond the ovary. The mass is removed intact wherever possible, because rupture and spillage raise the stage. Surgery of this kind is coordinated with specialist gynaecologic-oncology partner centres and may be billed there — CION arranges it with the surgical team rather than performing it in-house, and we would rather say that at the start than have you discover it at admission.
Peritoneal washings are taken, the abdominal surfaces, omentum and diaphragm are inspected, and anything abnormal is biopsied. Any deposits found are graded in their own right, separately from the ovarian tumour, which is what allows mature gliomatosis peritonei to be distinguished from genuinely immature implants. Incomplete staging is the commonest reason a young woman later ends up having a second operation, or receiving chemotherapy she may not have needed, so it is worth doing properly the first time.
Nothing else can be decided until the tumour has been examined under the microscope, which usually takes several days to a couple of weeks. This is the hardest part of the whole pathway for most families, because it is the part where there is nothing to do. Ask for the report to be explained rather than working from the summary line, and ask three specific questions: what grade, was the capsule intact, and was any other germ cell component found.
A grade 1 immature teratoma that was removed intact and fully staged can often be followed with close surveillance alone — examination, markers and periodic imaging — on the understanding that if it does return, it remains treatable. Paediatric practice has moved further towards surveillance after complete removal than adult practice has, which is one reason a young woman's case benefits from being discussed rather than decided by a single clinician. Beyond that, a short course of platinum-based combination chemotherapy is standard. Chemotherapy is delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh. More on ovarian cancer treatment in Hyderabad.
Most young women resume normal periods after treatment and are able to conceive naturally, because the uterus and one ovary have been kept and the chemotherapy course, where it is needed at all, is short. That is the usual outcome rather than the optimistic one. Even so, the conversation belongs before the first cycle rather than after the last — particularly where both ovaries are involved, where a longer course is planned, or simply where you want the additional security of preserving eggs or tissue first.
Follow-up is intensive for the first couple of years, when relapse is most likely, and eases off afterwards. One pattern is worth knowing about in advance: masses that grow during or after chemotherapy while the blood markers stay normal. This is growing teratoma syndrome, and what is enlarging is mature teratoma tissue, not active cancer. It does not respond to more chemotherapy and is managed by surgical removal, again coordinated with partner centres. Recognising it matters, because it is easily mistaken for treatment failure by everyone involved, including the patient.
Where you are treated matters more than usual with an uncommon tumour in a young patient. The decisions that go wrong in immature teratoma tend to be the early ones — a mass punctured or ruptured rather than removed intact, staging left incomplete, an ovary removed that did not need to be, or chemotherapy given for a grade 1 tumour that did not require it. The wider picture is in our guide to germ cell ovarian tumours in young women.
The person reading this is usually somewhere between fifteen and thirty, often with a parent reading over her shoulder, and the diagnosis has arrived in the middle of exams, or a first job, or a year that was supposed to be straightforward. What is needed on day one is rarely another test. It is someone with the time to explain what an immature teratoma is, what the grade on the report means, whether chemotherapy follows, and what happens to fertility — in that order, and without hedging.
Your first consultation at CION is free and runs to about 45 minutes. Bring the scan and the pathology report. Every case that raises a question is discussed at a tumour board rather than settled by one doctor, and that matters more here than it does for common cancers, precisely because this tumour is uncommon and because the difference between a grade 1 and a grade 2 report is the difference between surveillance and chemotherapy.
We are equally plain about who does what. Chemotherapy is delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, along with nutrition support, survivorship care and long-term follow-up, and genetic counselling where the wider family picture calls for it. Fertility-sparing surgery and surgical staging are coordinated with specialist gynaecologic-oncology partner centres and may be billed there. CION arranges that surgery and stays involved throughout it; we do not perform it ourselves, and you should hear that from us rather than find it out later.
One word on the numbers, because you will have looked them up. CION publishes its own one-year survival for ovarian cancer alongside the national figure: 81.0% of CION ovarian cancer patients are alive at one year, against a national figure of 73.7%. Both are one-year figures across an entire treated population — not cure rates, and not predictions for any individual. Both are also dominated by epithelial ovarian cancer in women over 50, which is a different disease from yours with a very different natural history, so published ovarian cancer statistics understate the outlook for an immature teratoma considerably. The figures worth discussing are the ones your oncologist can give you for this tumour, at this grade and stage.
Free, unhurried, and long enough to get through the grade, the surgery, chemotherapy and fertility in one sitting rather than across three visits.
Multidisciplinary review, which counts for more with an uncommon tumour where the grade sits on the line between surveillance and treatment.
Delivered by CION across Telangana and Andhra Pradesh, so treatment and follow-up can happen near where you live rather than in one city hospital.
Fertility-sparing and staging surgery is arranged with specialist gynaecologic-oncology partner centres and may be billed there.
*One-year survival rates across all ovarian cancer types and stages. CION figures reflect CION's treated patient population; national figures are drawn from published Indian cancer registry data. Both are dominated by epithelial ovarian cancer and describe groups rather than individuals — discuss the outlook for an immature teratoma specifically with your treating oncologist.
An immature teratoma is a malignant germ cell tumour of the ovary. Like all teratomas it is built from tissue belonging to all three layers of the early embryo, which is why these tumours can contain cartilage, skin, glandular tissue and hair. What makes this one a cancer is that some of the tissue inside it has not finished developing — almost always primitive neuroectoderm, the tissue that would otherwise have formed brain and nerve. It is the second commonest malignant ovarian germ cell tumour after dysgerminoma, occurs mainly in teenagers and women in their twenties, and usually presents as a rapidly enlarging pelvic mass rather than as vague long-standing symptoms. It is a different disease from the ovarian cancer most information online describes, which begins in the surface lining of the ovary and affects women over 50.
Yes, an immature teratoma is a cancer, and this is the single most common point of confusion. A dermoid cyst, properly called a mature cystic teratoma, belongs to the same family but everything inside it is fully formed tissue. It is benign: it is removed surgically, usually with the ovary preserved, and that is the end of the matter. An immature teratoma contains immature tissue as well, and that immature component is what makes it malignant. It needs surgical staging of the abdomen, and depending on the grade it may need chemotherapy afterwards. The two can look similar on an ultrasound, which is why the distinction is made by a pathologist examining the removed tumour rather than by any scan or blood test.
The grade describes how much immature tissue the pathologist can find on the slide containing the most of it. A trace makes it grade 1; readily visible immature tissue across the field makes it grade 3, with grade 2 in between. The current WHO classification asks for this to be reported in two tiers instead — low grade, meaning grade 1, and high grade, meaning grades 2 and 3 — because that is the division treatment actually turns on. It matters more than in most cancers, because in immature teratoma the grade rather than the stage usually decides what follows surgery. A grade 1 tumour removed intact and properly staged is often followed with surveillance alone. A high-grade tumour usually leads to a conversation about chemotherapy.
Not necessarily, and this is the question the grade answers. A grade 1 immature teratoma that was removed intact, with complete surgical staging showing no spread, can often be followed with close surveillance instead of chemotherapy — regular examination, tumour markers and periodic imaging — on the understanding that if it does return, it is still treatable. Paediatric practice has moved further in this direction than adult practice, which is one reason a young woman's case is better discussed at a tumour board than decided by one clinician. Where the tumour is high grade, where it ruptured, where staging was incomplete or where disease had spread, a short course of platinum-based combination chemotherapy is standard. CION delivers that chemotherapy in-house across more than 35 centres.
In most cases, yes. Standard surgery removes only the affected ovary and its tube and leaves the uterus and the opposite ovary in place, and that holds even for many young women whose disease has spread, because chemotherapy does the rest of the work. Where chemotherapy is needed at all it is a short course, and most young women resume normal periods afterwards and conceive naturally. That is the usual outcome rather than the hopeful one. Fertility preservation is still worth discussing before treatment begins, particularly if both ovaries are involved, if a longer course of chemotherapy is planned, or simply if you want the additional security. Have that conversation before the first cycle rather than after the last, because the options narrow once treatment has started.
This pattern has a name: growing teratoma syndrome. Masses enlarge during or after chemotherapy while the tumour markers stay normal, and when they are removed and examined they turn out to contain only mature teratoma tissue — not active cancer. It is thought to happen because chemotherapy clears the immature, malignant component and leaves the mature tissue behind to keep growing. It does not respond to more chemotherapy, and giving more is the wrong answer. It is managed surgically, by removing the masses, coordinated with specialist gynaecologic-oncology partner centres. Recognising it matters, because from the outside it looks exactly like treatment failure and can be frightening for everyone involved, including the treating team if they have not seen it before.
The first consultation is free and runs to about 45 minutes — bring the scan and the pathology report, since the grade written on it is what decides whether chemotherapy is needed at all. Chemotherapy is delivered in-house at CION across more than 35 centres in Telangana and Andhra Pradesh, alongside nutrition support, survivorship care and long-term follow-up, and genetic counselling where the wider family picture calls for it. Fertility-sparing surgery, surgical staging and any surgery for growing teratoma syndrome are coordinated with specialist gynaecologic-oncology partner centres and may be billed there; CION arranges that surgery and stays involved through it rather than performing it in-house. Every case is reviewed at a tumour board, which counts for more with an uncommon tumour in a young patient.